From a licensed seller that names its pharmacy, reasonably; from an unnamed source on the open internet, nobody can tell you, and the published record is thinner than either side of that argument pretends.
What has been measured is the product rather than the transaction. Laboratory analysis of follow-on and compounded semaglutide against the originator found distinct impurity profiles — amino acid deletions and additions, and unidentified impurities [2]. Compounded semaglutide showed disparities in strength and in high-molecular-weight protein after light exposure. ⛔ Every author is an employee and shareholder of the company that makes both originators. That does not make the assay wrong, but it does mean the copies were tested by the company that makes the original.
The market itself has been counted. After the shortage ended, a survey of the compounded market in two high-demand states found most sellers offering the peptide mixed with other ingredients [3], which is what the rule change produced. And a survey of community pharmacists found that over 60% of requests were made with no prescription at all [4], so a large share of demand is already trying to skip the gate.
This is a single case report with a bacterial infection sitting in the middle of it, which makes it useless as evidence that a product caused harm. It is genuinely useful as a picture of what happens when nobody can say what was in the vial. It is the question the antidoping paper approached from the laboratory side.
What happened
Retatrutide is investigational. It is being studied for obesity and type 2 diabetes, it has no established role in type 1, and it is not sold to consumers. [1] The product in this case was purchased online and marketed as retatrutide.
Shortly after injecting it the patient developed severe vomiting and diarrhea, high blood glucose, ketones in the blood and acute kidney injury. Ketones reached 4.3 mmol/L. He was treated with intravenous insulin and fluids, and during recovery had repeated episodes of low blood sugar that needed dextrose and insulin adjustment.
Why type 1 diabetes is the dangerous setting
People with type 1 depend on injected insulin to stop the body producing ketones. A stomach bug that stops someone eating, and a dose skipped because they are not eating, can push ketones up quickly.
That is standard sick-day physiology and it does not require an unapproved drug. It is also the reason a product bought without any medical assessment or sick-day counseling is a worse idea here than almost anywhere.
So what is the finding
Not a risk estimate. The finding is diagnostic. When a patient arrives unwell having taken something nobody can identify, every decision after that is made on incomplete information, and the authors say clinicians in non-specialist settings may not know these agents exist.
The advice at the end of the paper is aimed at doctors — ask about non-prescribed agents when someone presents with unexplained metabolic trouble. The half aimed at a buyer is simpler: a product whose composition, purity and dosing accuracy are unknown is also a product your doctor cannot account for.
Contents unknown
The paper does not report any analysis of what the vial contained, and nobody assayed it. So there is no way to know whether it held retatrutide, a different peptide, the wrong amount, or something else entirely.
That gap is not hypothetical. It is what happens when researchers ordered these products and tested what turned up. It is also why the dispensing route matters at all. The difference between the two kinds of compounding pharmacy is about oversight, and an online vendor sits outside both.
How to weigh a case report
Barely at all, as evidence. A single patient cannot establish a rate, a risk or a cause, and this one has a bacterium in it.
What it can do is describe a pathway nobody had written down. That is different from a database of tens of thousands of reports, which also cannot establish a rate, for entirely different reasons.